NCT02065973View on ClinicalTrials.gov

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 30, 2015

Study Completion Date

December 30, 2015

Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Interventions
BIOLOGICAL

R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7

Trial Locations (2)

10467

Montefiore Medical Center, The Bronx

11777

Suffolk Obstetrics & Gynecology, Port Jefferson

Sponsors
All Listed Sponsors
lead

PDS Biotechnology Corp.

INDUSTRY